Author:
Kaku Kohei,Haneda Masakazu,Sakamaki Hiroyuki,Yasui Atsutaka,Murata Tatsunori,Ustyugova Anastasia,Chin Rina,Hirase Tetsuaki,Shibahara Tsunehisa,Hayashi Naoyuki,Kansal Anuraag,Kaspers Stefan,Okamura Tomoo
Funder
Boehringer Ingelheim Co. Ltd
Eli Lilly and Company
Subject
Pharmacology (medical),Pharmacology
Reference33 articles.
1. Ministry of Health, Labour and Welfare. Japan National Health and Nutrition Survey, FY2016. https://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/kekkagaiyou_7pdf, Accessed 29 August 2019.
2. International Diabetes Federation. https://www.idf.org/our-activities/care-prevention/cardiovascular-disease.html, Accessed 29 August 2019.
3. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the Committee on Causes of Death in Diabetes Mellitus;Nakamura;J Diabetes Investig,2017
4. An overview of regular dialysis treatment in Japan as of Dec,2017
5. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes;Grempler;Obes Metab,2012
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献